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ABSTRACT
Abdominal aortic aneurysms (AAAs) are an important
cause of morbidity and, when ruptured, are associated
with >80% mortality. Current management decisions are
based on assessment of aneurysm diameter by
abdominal ultrasound. However, AAA growth is non-
linear and rupture can occur at small diameters or may
never occur in those with large AAAs. There is a need to
develop better imaging biomarkers that can identify the
potential risk of rupture independent of the aneurysm
diameter. Key pathobiological processes of AAA
progression and rupture include neovascularisation,
necrotic inflammation, microcalcification and proteolytic
degradation of the extracellular matrix. These processes
represent key targets for emerging imaging techniques
and may confer an increased risk of expansion or rupture
over and above the known patient-related risk factors.
Magnetic resonance imaging, using ultrasmall
superparamagnetic particles of iron oxide, can identify
and track hotspots of macrophage activity. Positron
emission tomography, using a variety of targeted tracers,
can detect areas of inflammation, angiogenesis, hypoxia
and microcalcification. By going beyond the simple
monitoring of diameter expansion using ultrasound,
these cellular and molecular imaging techniques may
have the potential to allow improved prediction of
expansion or rupture and to better guide elective
surgical intervention.
INTRODUCTION
Abdominal aortic aneurysm (AAA) disease affects
up to 5% of men aged between 65 and 74 years in
Western Europe and may pass undetected until a
patient presents with rupture. The mortality rate of
ruptured AAA is over 80%,1 with a minority of
patients surviving long enough to undergo emer-
gency repair. The risks associated with elective
AAA repair are also significant, with a 30-day mor-
tality rate of up to 5% for elective endovascular or
open repair.2 Decision-making at an individual
patient level is therefore paramount to ensure the
best clinical outcome, particularly as AAA shares
risk factors for, and typically coexists with, athero-
sclerotic disease processes that confer substantial
perioperative risk.
When planning management of a patient with
an AAA, the risks of elective surgery must be
weighed against the risk of rupture without inter-
vention. Various risk prediction models have been
developed to help evaluate perioperative and post-
operative risk. While these scores may help evalu-
ate risk when operative intervention is being
considered, the prediction of aneurysm expansion
and rupture risk in patients under surveillance
remains challenging. Current knowledge of AAA
progression is largely based on the tenet that
rupture rate rises with increasing aneurysm diam-
eter. However, up to one in five ruptured AAAs
occur in small aneurysms (<5.5 cm),3 while many
patients have far larger aneurysms that never
rupture and a substantial proportion of patients
die of non-AAA-related causes while under surveil-
lance. We would therefore suggest that prediction
of disease progression using simple measures and
thresholds, such as aneurysm diameter, is too
simplistic.
RISK FACTORS FOR DISEASE OCCURRENCE
AND PROGRESSION
Various risk factors for the development and
progression of AAA disease have been identified,
although it remains unclear why some patients
develop AAA and others, with identical risk pro-
files, do not. AAA occurrence is associated with
advancing age and male sex. However, female
sex is also an independent predictor of acceler-
ated disease progression. Indeed, in comparison
to men, women have an increased rate of aneur-
ysm expansion and a threefold higher risk of
rupture.4 Moreover, when rupture takes place in
women, it occurs at smaller aneurysm
diameters.5
Cigarette smoking is the most important modifi-
able risk factor associated with development,
expansion and rupture of AAA: more than 90% of
patients with AAA are current or ex-smokers. The
relative risk of aneurysm development in current
smokers is at least 2,6 with an increased rate of
expansion of the order of 15–20% in patients who
continue to smoke.7
Although it is often said that AAA shares much
of its pathophysiology with atherosclerosis, it has a
number of distinct features. While traditional ath-
erosclerotic risk factors (such as hypertension and
hypercholesterolaemia) are also associated with
AAA formation, diabetes mellitus is protective
against its development.8 The reason for this
remains incompletely understood but may relate to
diabetes-mediated inhibition of the matrix metallo-
proteinases (MMPs)9 that are responsible for pro-
teolytic degradation of the extracellular matrix in
AAA disease. The pleiotropic effects of antidiabetic
medications, including lipid homeostasis, may also
be important.10
A strong genetic component to the development
of AAA is suggested by the observation that
patients with a family history of AAA have the
highest risk of AAA development.11 Connective
tissue diseases, such as Marfan’s syndrome and
Ehlers–Danlos syndrome, are also associated with
AAA development.
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TOWARDS IMPROVED EVALUATION OF DISEASE
PROGRESSION
Current evaluation of AAA disease progression is based on mor-
phological risk factors for expansion—primarily, aneurysm
diameter. Serial ultrasound examination is the standard method
of monitoring the natural history of AAA disease, using
population-derived data to predict the future expansion of an
individual patient’s aneurysm. The establishment of population-
based ultrasound screening in the UK has been associated with a
40–50% decrease in aneurysm-related mortality.1 Overall, the
rate of expansion and risk of rupture generally rises with
increasing AAA diameter, and current guidelines recommend
that elective repair should be considered when the AAA exceeds
5.5 cm in maximum anteroposterior diameter, or expansion
exceeds 1.0 cm/year.
Recent data have demonstrated that many aneurysms exhibit
a non-linear, discontinuous staccato growth pattern, with
periods of expansion and dormancy.12 The specific biomechan-
ical and biological factors that lead to this variable and patient-
specific AAA expansion patterns cannot be accounted for by
current aneurysm diameter measurements and recent growth
trends alone. Despite this, maximum anteroposterior diameter,
as measured on ultrasound or computed tomography (CT), is
still considered the best clinical predictor of AAA expansion and
rupture.7
Morphological features associated with disease progression
include vessel asymmetry13 and a short, narrow neck configur-
ation.14 The role of intraluminal thrombus in disease progres-
sion remains controversial, although plausibly a large thrombus
load may induce local wall hypoxia, triggering further inflam-
matory activity and inducing changes in local wall strength,15
potentially leading to rupture. However, beyond maximum
diameter none of these is validated as part of standard monitor-
ing of patients with AAA.
As a tool for aneurysm growth surveillance, ultrasound is
ideally suited since it is relatively inexpensive, readily available
and avoids ionising radiation. CT offers the additional anatom-
ical information required for surgical planning and can diagnose
rupture. However, neither modality offers insight into the bio-
logical status of the aneurysm that determines disease progres-
sion. Future developments in the assessment of AAA disease
should go beyond simple morphological parameters with the
aim of predicting more accurately the likely evolution of the
aneurysm for an individual patient.
PATHOBIOLOGICAL ACTIVITY AS TARGETS FOR DISEASE
MONITORING: BIOLOGICAL ‘HOTSPOTS’
Aneurysmal degeneration of the aorta involves inflammation,
neovascularisation, microcalcification and proteolytic degrad-
ation of the extracellular matrix culminating in medial thinning
and loss of the structural integrity of the vessel wall. Once
again, there are common pathological processes involved in
both AAA and atherosclerosis, but also some clear differences
(figure 1). Perhaps, the most striking difference is that athero-
sclerosis affects the arterial intima, causing luminal narrowing,
whereas aneurysmal degradation of the vessel wall predomin-
antly affects the media and adventitia, causing vessel dilatation.
Furthermore, while aneurysm disease affects only the distal
abdominal aorta in 90% of cases, atherosclerosis is typically
widespread involving the coronary, cerebral and peripheral cir-
culation systems.
In studies of coronary atherosclerosis, the term ‘vulnerable
plaque’ has been coined to describe plaques at risk of rupture
precipitating clinical events. Such plaques are characterised by
pathological features that include a thin fibrous cap, large lipid
core, increased infiltration of macrophages and a reduction in
smooth muscle cells.16 Analogous to this concept, ‘hotspots’
have been described in AAA, reflecting the focal and intense bio-
logical activity that occurs in specific regions of the aortic wall.
Within these hotspots, focal neovascularisation is associated
with increased inflammation and proteolysis and is present at
the site of rupture.17 In contrast, the tensile strength of the
aortic wall is not uniform and is impaired in areas of increased
proteolytic activity,18 which varies across the aneurysm sac.
These biological hotspots appear to represent areas of the aortic
wall that are prone to further expansion and rupture.
A number of serum biomarkers of inflammatory and proteo-
lytic activity have been investigated in patients with AAA includ-
ing MMPs (MMP-2, MMP-8, MMP-9), interleukins (IL-6,
IL-10), CRP and other potential mediators (including TNF-α
and TIMP-1) that may contribute to connective tissue degrad-
ation and depletion of collagen and elastin stores. Increased
levels of MMP-8 and MMP-9 have also been identified at the
site of AAA rupture.19 However, measurement of plasma con-
centrations of these biomarkers has not been demonstrated to
be of value in clinical risk prediction of patients and this likely
reflects a lack of sensitivity. Ultimately plasma concentrations
will represent activity of the entire vasculature rather than
potentially small areas of focal vascular injury.
The identification of biological hotspots within the aortic wall
using non-invasive imaging may prove to be a more valuable
approach that could enable risk prediction and, in addition to
the other known risk factors for AAA progression, could form
part of a patient-specific risk prediction model. However, this
cannot be achieved using conventional cross-sectional imaging
techniques and contrast agents. Molecular imaging techniques
have the potential to provide such functional biological informa-
tion and, when used in combination with structural anatomical
data, may provide regional and patient-specific information on
disease activity. Capitalising on our increased knowledge of the
pathogenesis of cardiovascular disease, the field of ‘molecular
imaging’ is one area that has expanded rapidly over the past few
decades. Molecular imaging techniques apply both positron-
emission tomography (PET) and magnetic resonance imaging
(MRI) to identify cell-specific or process-specific probes that
assess the biological function of small-scale molecular events,
such as gene transcription, or identify surrogate markers for
disease activity, such as inflammation and calcification.
Knowledge of a relevant biological ‘target’ is a prerequisite. A
suitable tracer needs to be able to bind to the target, be clinically
available and offer compatibility with a clinically available
imaging modality that provides appropriate spatial and tissue
resolution for the disease process. Such techniques have been
used in coronary artery disease and valvular heart disease to
describe key processes involved in atherosclerosis including
inflammation, angiogenesis and apoptosis.20 21 These techniques
can often define and identify evolving disease states at an earlier
stage than conventional imaging such as the identification of
vulnerable lesions associated with plaque rupture and myocar-
dial infarction. Similarly, the identification, localisation and
tracking of disease activity in patients with AAA may provide
incremental risk prediction in addition to known risk factors for
disease progression (figure 2).
MACROPHAGE ACTIVITY AND MRI
MRI offers high spatial resolution, avoids ionising radiation and
results in excellent soft tissue contrast. Molecular MRI
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techniques allow coregistration of molecular information with
detailed anatomical information and can also be fused with CT
data. Paramagnetic MRI agents (such as gadolinium) are used
widely in clinical practice. When used as a blood pool agent in
AAA, T2-weighted gadolinium-enhanced MRI delineates mor-
phological features such as the blood pool, thrombus and
fibrous cap22 whereas late enhancement reveals areas of fibrosis
within vascular tissues. More recently, ultrasmall superparamag-
netic particles of iron oxide (USPIOs) have been used as ‘smart’
contrast agents in cardiovascular molecular MRI studies.23 24
USPIOs exhibit a dual benefit, in that they can be used both as
an initial T1 blood-pool contrast agent as well as visualise tissue
inflammation using delayed T2 and T2* imaging. Moreover,
USPIOs can be safely used in patients with renal failure,
whereas the use of gadolinium is contraindicated in patients
with renal failure, due to the risks of nephrogenic systemic
fibrosis. With a mean particle diameter of <50 nm, USPIOs are
small enough to evade immediate uptake by the reticuloendo-
thelial system and persist in the blood pool with a half-life of
10–15 h. They translocate into tissues and are slowly taken up
by tissue-resident macrophages thereby accumulating at sites of
inflammation. As such, they have been used to identify and
track macrophage activity in situations of cardiovascular disease.
In particular, they have been shown to accumulate in vulnerable
and ruptured atherosclerotic plaques, but not stable plaques,
and atorvastatin therapy reduces USPIO uptake and inflamma-
tion in symptomatic carotid plaques.25 More recently, a small
pilot study of 29 patients with asymptomatic AAA (diameter
between 4 and 6.6 cm) has demonstrated that focal areas of
USPIO uptake in the aortic wall are associated with more rapid
AAA expansion.23 A large, prospective multicentre trial
(ISRCTN76413758) of USPIO to predict AAA rupture or
surgery in patients with asymptomatic AAA (n=350) is currently
in progress.26 This will establish whether this imaging approach
has any potential clinical utility in patient monitoring (figure 3).
Further development of MRI-based techniques may include
development of agents that can detect subgroups of macro-
phages, in addition to other aspects involved in the process of
atherosclerosis and AAA disease progression.
MACROPHAGE ACTIVITY AND PET
There is a wide range of PET tracers available that can target
different disease processes, many of which could be used in car-
diovascular disease. PET has lower spatial resolution (∼5 mm)
when compared with MRI or CT, and on its own cannot
provide optimal anatomical information for detailed evaluation.
However, fusion techniques (PET-CT and PET-MRI) allow the
integration of molecular information obtained through PET
with anatomical detail gained from CT or MRI. Macrophage
activity may be tracked using cell-specific PET tracers (table 1).
Figure 1 Comparison of pathobiological characteristics of atherosclerosis and abdominal aortic aneurysm (AAA) disease. While AAA disease shares
similar pathobiological processes involved in atherosclerotic disease, there are notable distinctions. In particular, the location of the disease
processes is an important difference, with atherosclerosis affecting primarily the vessel intima, whereas AAA disease has a predilection for the media
and adventitia. The resulting clinical manifestation is that AAA disease causes vessel dilatation and rupture, whereas atherosclerosis leads to vessel
stenosis occlusion. However, the common ground between these two pathological conditions means that molecular imaging techniques thus far
used in the study of atherosclerotic vessels (such as the coronary and carotid arteries) may prove useful in the study of AAA disease.
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18F-Fluorodeoxyglucose
The most widely used clinical PET tracer is
18F-fluorodeoxyglucose (18F-FDG): a glucose analogue that is
taken up by glucose transporters and accumulates in glucose-
metabolising cells. It is used as a surrogate marker for metabolic
activity and is widely used to identify tumour metastases and
monitor response to cancer treatment. In addition, its value in
atherosclerosis imaging (by identifying metabolically active
macrophages as a marker of inflammation) has been explored
largely in the coronary and carotid arteries, as it accumulates
within active atherosclerotic plaques.27
18F-FDG imaging is the only clinically available tracer that
has been explored in AAA disease but its value remains unclear.
One small study found that AAA wall biopsies from patients
with 18F-FDG uptake showed significantly increased inflamma-
tory infiltrate and a reduction in the number of smooth muscle
cells compared with samples from patients with no 18F-FDG
uptake.28 Another small study showed that patients undergoing
open repair of symptomatic AAA (n=3) had higher 18F-FDG
uptake than asymptomatic patients (n=12), and increased
18F-FDG uptake correlated with histological evidence of
increased inflammatory activity.29 Increased 18F-FDG uptake
within the AAA was associated with more aneurysm-related clin-
ical events compared with patients with no 18F-FDG uptake,
and interestingly areas of 18F-FDG uptake correlated with
increased wall stress on biomechanical modelling.30 The authors
of these papers suggest a potential role of 18F-FDG PET
imaging in predicting AAA expansion or rupture.
However, the value of 18F-FDG uptake remains controversial.
Data sets are generally small and often derived retrospectively
from oncology patient cohorts. Moreover, one larger study has
demonstrated no difference in 18F-FDG uptake among patients
with AAA when compared with matched controls (n=310).31
An inverse relationship between 18F-FDG uptake and future
AAA expansion has been demonstrated in a small study, suggest-
ing that aneurysms with lower metabolic activity may actually
be more prone to expand.32
The primary drawback of 18F-FDG PET imaging is that the
effect of local cellular hypoxia on glucose uptake may confound
the PET signal that is otherwise attributed to macrophage activ-
ity,33 as well as the potential for spillover from adjacent struc-
tures that are metabolically active, such as muscle and liver.
Thus, 18F-FDG PET imaging of AAA entails many potential
confounding factors, lacks specificity and there is currently
insufficient evidence to support its routine clinical use in pre-
dicting future AAA expansion or rupture risk.
Although other experimental PET tracers have been investi-
gated in studies of inflammation in the context of atherosclerotic
plaque, few have been investigated in AAA disease. As aneurysm
disease shares some of the common pathways involved in ath-
erosclerosis, some of these tracers may prove useful in the evalu-
ation of AAA disease.
Figure 2 Biological targets and potential molecular imaging techniques in abdominal aortic aneurysm (AAA) disease. As well as patient factors
(such as smoking, hypertension and advancing age) that contribute to the risk of AAA formation, biological processes have been identified that are
implicit in aneurysm formation. The key processes are illustrated above, along with the corresponding molecular imaging techniques (written in
green arrows) that have been used in experimental or clinical studies to date (primarily in the coronary arteries). The combination of patient-related
risk factors and biological processes leads to increased wall stress and decreased wall strength (which can be investigated using computational
modelling techniques), and all of these factors lead to aneurysm expansion and vulnerability to rupture.
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68Ga-DOTATATE
68Ga-DOTATATE (68Ga-[1,4,7,10-tetraazacyclododecane-N,N0,
N00,N0-tetraacetic acid]-d-Phe1,Tyr3-octreotate) has a specific
binding affinity for somatostatin receptors, which play a role in
the modulation of inflammation and angiogenesis. Activated
macrophages and damaged endothelial cells can cause overex-
pression of somatostatin receptors (subtype 2), and
68Ga-DOTATATE (which binds to these receptors) exhibits
macrophage-specific binding properties that may be more valu-
able than 18F-FDG. Murine studies have demonstrated
68Ga-DOTATATE uptake in atherosclerotic plaques,34 while
clinical imaging studies have demonstrated an association
between 68Ga-DOTATATE uptake in coronary arteries and
known cardiovascular risk factors such as the presence of
calcified plaques and hypertension.35 Of note, focal uptake of
68Ga-DOTATATE does not always correlate with 18F-FDG
uptake in one comparison study, suggesting that these tracers
target slightly different pathobiological pathways. There have
been no studies to date investigating the role of
68Ga-DOTATATE in AAA disease progression; however, the
abundance of macrophages seen in aneurysmal aortic wall sug-
gests that this may be a suitable tracer for evaluation.
11C-PK11195 and GE180
11C-PK11195 and GE180 selectively bind to the translocator
protein (TSPO) and have been used primarily in the assessment
of neuronal damage. However, TSPO are also highly expressed
by activated macrophages. Studies have demonstrated the
Figure 3 Magnetic resonance imaging (MRI) using ultrasmall superparamagnetic particles of iron oxide (USPIO) in abdominal aortic aneurysm
disease. This technique is currently being investigated in the MA3RS study (MRI in Abdominal Aortic Aneurysms to Predict Rupture or Surgery—
ISRCTN76413758).
Table 1 PET radiotracers with potential value to track disease processes in AAA
Radiotracer
(references)
Pathobiological
process Cellular target Molecular target
Current clinical
use Applications and limitations
18F-FDG27–33 Inflammation Macrophage Glucose analogue Yes—oncology,
neurology and
cardiology
Uptake influenced by local hypoxia and other resident cell
types, therefore may have limited value. Widely used in
cardiovascular research; has been studied in AAA disease
68Ga-DOTATATE34–35 Inflammation Macrophage Somatostatin
receptor (subtype 2)
Experimental No physiological uptake seen in myocardium, therefore
clearly detects macrophage accumulation
11C-PK1119536 Inflammation Macrophage TSPO receptor Experimental Non-specific binding and low arterial signal density may
preclude its use in clinical setting
GE18047 Inflammation Macrophage TSPO receptor Experimental Binding heterogeneity—10% of the population may lack
binding potential due to variant in receptor
18F-FMCH37–39 Inflammation Macrophage Choline receptor Yes—oncology High uptake in liver may obscure analysis in suprarenal
aorta. Lower tissue-to-background ratios than FDG,
however, may identify areas of evolving inflammation
distinct from areas of established calcification
18F-fluciclatide47 Angiogenesis Endothelium,
fibroblasts
Integrin αvβ3 Experimental Has been investigated in autoradiography studies of AAA
disease
18F-FMISO48 Hypoxia Macrophage Macromolecules in
hypoxic cells
Experimental Has been used in carotid studies
18F-HX448 Hypoxia Macrophage Macromolecules in
hypoxic cells
Experimental Has been used in carotid studies
18F-NaF46 Microcalcification – Hydroxyapatite Yes—oncology Overspill from nearby bone can interfere with uptake
interpretation
AAA, abdominal aortic aneurysms; DOTATATE, 68Ga-[1,4,7,10-tetraazacyclododecane-N,N0,N00 ,N0-tetraacetic acid]-D-Phe1,Tyr3-octreotate; FDG, fluorodeoxyglucose; FMCH,
fluoromethylcholine; FMISO, fluoromisonidazole; HX4, (3-[18F]fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3,-triazol-1-yl)-propan-1-ol); NaF, sodium fluoride; PET,
positron-emission tomography; TSPO, translocator protein.
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potential use of 11C-PK11195 in localising vascular inflamma-
tion in atherosclerotic disease states such as symptomatic carotid
artery disease and inflamed aortic plaques.36 GE180 has a
superior signal-to-noise ratio compared with 11C-PK11195;
however, around 10% of people may have a genetic variant in
the GE180 receptor, which leads to poor binding of the ligand.
Binding heterogeneity would be a barrier to widespread use of
GE180, as it would require pre-emptive genotyping. Neither
tracer has been investigated in AAA disease to date.
18F-Fluoromethylcholine
18F-Fluoromethylcholine (18F-FMCH) binds to choline recep-
tors and was introduced as a radiotracer for neuroimaging and
prostate cancer. However, increased choline uptake is also seen
in activated macrophages. 18F-FMCH uptake has been seen in
murine atherosclerotic plaques, with a higher sensitivity than
18F-FDG,37 while one retrospective clinical study in oncology
patients demonstrated 18F-FMCH uptake in structurally abnor-
mal aortic wall,38 but not in areas that only exhibited established
calcification. This suggests that 18F-FMCH may identify areas of
current biological activity, distinct from areas of macroscopic
calcification that are biologically inert. However, a comparison
study of rat AAA has demonstrated that 18F-FMCH achieved
lower tissue-to-background ratios than 18F-FDG, which was
more sensitive when detecting activated macrophages.39
CALCIFICATION IN AAAS
Vascular calcification is associated with increased cardiovascular
risk. Molecular imaging studies have suggested that inflamma-
tion and calcification occur at different stages of the atheroscler-
otic disease process.40 18F-FDG does not always colocalise with
areas of calcification seen on CT,41 and it is postulated that vas-
cular calcification occurs as part of the healing response to nec-
rotic inflammation, and is regulated in a similar manner to bone
formation.42 Established deposits of vascular calcification are
considered part of a chain of pathological processes relating to
atherosclerosis.41 Therefore, macroscopically visible vascular cal-
cification (macrocalcification) may correlate with overall disease
burden and can be visualised on CT.
Mural calcification is common in AAA disease, is a predictor
of future cardiovascular events and may also be linked with an
increased risk of rupture.43 Calcification, resulting from necrotic
inflammation, may therefore cause aneurysm wall weakness.44
Although widespread macrocalcification is very common in
AAA disease, macrocalcification on CT does not identify those
at high risk of AAA events. However, early evolving areas of cal-
cification (microcalcification) could be a more significant and
useful measurement of biological activity in the aneurysm wall,
as microcalcification precedes the laying down of macrocalcifica-
tion. Recent evidence suggests that plaque vulnerability is
inversely associated with calcification density—established dense
calcification may stabilise a plaque whereas less dense, spotty
areas of microcalcification can trigger plaque rupture by causing
a disproportionate increase in local stresses in the thin collage-
nous plaque, leading to a mismatch in compliance and vulner-
ability to rupture.45 Identifying and localising microcalcification
are beyond the resolution of CT scanning and require a molecu-
lar imaging approach to detect its presence.
MICROCALCIFICATION AND 18F-NAF PET IMAGING
The PET radiotracer 18F-sodium fluoride (18F-NaF) has been
used as a bone tracer for decades in the clinical arena. 18F-NaF
acts as a novel marker of vascular calcification activity, by
binding to hydroxyapatite, which is a key component of bone
and vascular calcification. 18F-NaF preferentially binds to areas
of developing calcification (microcalcification) and has been
used to identify high-risk coronary plaques and culprit lesions
in acute myocardial infarction.46 18F-NaF may also be useful in
Figure 4 18F-NaF positron emission tomography–computed tomography (PET-CT) in abdominal aortic aneurysm disease. This technique is currently
being investigated in the SoFIA3 study (Sodium Fluoride Imaging (18F-NaF PET-CT) in Abdominal Aortic Aneurysms—NCT02229006).
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patients with AAA to identify those with increased biological
activity. Microcalcification represents necrotic inflammation
which, in turn, weakens the vessel wall and may predispose to
aneurysm expansion or rupture. By combining 18F-NaF PET
with CT and CT angiography, identification of hotspots of
increased microcalcification in the aneurysm wall could allow
identification of high-risk AAAs. These data, when combined
with known clinical risk factors for disease progression, may
allow patient-specific evaluation of AAA expansion or rupture
risk. This is currently being investigated as part of the prospect-
ive sodium fluoride imaging (18F-NaF PET-CT) in AAAs
(SoFIA3) study (NCT02229006) (figure 4).
OTHER TARGETS FOR MONITORING BIOLOGICAL ACTIVITY
Other potential PET tracers that may be useful in evaluating
AAA disease do exist,47 although research has so far been con-
fined largely to preclinical autoradiography studies.
18F-fluciclatide binds to integrins and has a high affinity for
αvβ3, which is expressed on endothelial cells, fibroblasts and
inflammatory cells, and is known to be upregulated in angiogen-
esis. One autoradiography study demonstrated that
18F-fluciclatide detects areas of angiogenesis in AAA in vitro.47
18F-FMISO (fluoromisonidazole) and 18F-HX4 are radiotracers
that selectively identify areas of hypoxia and have been used to
localise high-risk carotid artery plaque reflecting increased
macrophage activity.48 Proteolytic degradation of collagen and
elastin in the extracellular matrix is another key component in
AAA formation. Gadolinium-based contrast agents, using MRI
tropoelastin-binding probes, have recently shown promise in
imaging impaired elastinogenesis in atherosclerotic mice49 and
in humans following myocardial infarction.50
CONCLUSIONS AND FUTURE CHALLENGES
Current evaluation of AAA disease (using the basic morpho-
logical parameter of maximum aneurysm diameter) facilitates
only a generic, population-based estimate of future aneurysm
progression. However, more sophisticated methods of risk pre-
diction are now required to plan timely surgical intervention, to
allow appropriate screening intervals during AAA surveillance
and to rationalise health resources.
While aneurysm disease shares some of the common path-
ways of atherosclerosis, its unique and, as yet, incompletely
understood pathobiology means that further AAA-specific
research is required to assess the value of promising imaging
techniques that have been explored in the carotid and coronary
arteries. There is a pressing need to understand the evolving
biology of AAAs and its contribution to future AAA-related
events. Emerging molecular imaging techniques offer the poten-
tial to add this additional biological information to the estab-
lished risk factors for disease progression and may facilitate
individual patient risk assessment.
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